E Fund CSI Innovative Drugs ETF(516080) Falls 2.76%, Attracting RMB 92.7691 Million Over Past 8 Days

NewTimeSpace News — As of 11:06 on April 17, 2026, E Fund Innovative Drug ETF (516080) fell 2.76%, with the latest price at RMB 0.67. Looking at a longer time horizon, as of April 16, 2026, the ETF had cumulatively increased 2.69% over the past week, ranking 2nd out of 7 comparable funds in terms of gains. (The stocks listed above are index constituents only, with no specific recommendation intended.)

In terms of liquidity, E Fund Innovative Drug ETF recorded an intraday turnover rate of 3.76% and trading volume of RMB 52.9724 million. Extending the timeframe, as of April 16, the ETF's average daily trading volume reached RMB 70.2357 million over the past week, placing it in the top 3 among comparable funds.

Regarding scale, E Fund Innovative Drug ETF's latest assets under management stood at RMB 1.422 billion, hitting a new high for the past year and ranking 3rd out of 7 comparable funds. (Data Source: Wind)

In terms of shares outstanding, the ETF's latest shares outstanding reached 2.074 billion shares, hitting a new high for the past year and ranking 3rd out of 7 comparable funds. (Data Source: Wind)

From the perspective of net capital inflows, E Fund Innovative Drug ETF has recorded consecutive net inflows over the past 8 days, with a peak single-day inflow of RMB 28.0022 million, totaling RMB 92.7691 million in "capital attraction," and an average daily net inflow of RMB 11.5961 million. (Data Source: Wind)

Data indicates continued positioning by leveraged funds. E Fund Innovative Drug ETF has recorded net margin purchases for 3 consecutive days, with a peak single-day net purchase of RMB 7.2475 million, and the latest margin balance at RMB 42.8464 million. (Data Source: Wind)

As of April 16, E Fund Innovative Drug ETF has risen 37.61% in net asset value over the past 2 years, ranking first among comparable funds. In terms of return capability, as of April 16, 2026, since its inception, the ETF's highest monthly return was 22.96%, with the longest consecutive rising streak lasting 5 months and a maximum consecutive gain of 33.43%. The average monthly return during rising months was 5.75%. As of April 16, 2026, the ETF has achieved an annualized excess return over the benchmark of 3.19% over the past 2 years, ranking 1st out of 7 comparable funds.

Regarding drawdown, as of April 16, 2026, the ETF's drawdown relative to the benchmark this year was 0.05%, representing lower drawdown risk among comparable funds.

In terms of fees, E Fund Innovative Drug ETF charges a management fee of 0.15% and a custody fee of 0.05%, representing the lowest fee structure among comparable funds.

Regarding tracking accuracy, as of April 16, 2026, the ETF's tracking error over the past 2 months was 0.012%, representing relatively high tracking precision among comparable funds.

From a valuation perspective, the CSI Innovative Drug Industry Index tracked by E Fund Innovative Drug ETF currently has a price-to-earnings ratio (PE-TTM) of only 43.78x, standing at the 6.11th percentile over the past year, meaning the valuation is lower than 93.89% of the time over the past year, placing it at a historical low.

E Fund Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index, which selects up to 50 most representative listed companies whose main business involves innovative drug research and development as index constituents, to reflect the overall performance of securities of companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.